This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

Minimal residual disease was “strongly” associated with overall survival at the patient level, researchers reported. Minimal residual disease (MRD) is “a credible intermediate endpoint” for some ...

Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 ...

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...

Revuforj shows a 63.9% overall response rate in relapsed/refractory KMT2Ar acute leukemia, with significant MRD negativity and HSCT progression rates. The AUGMENT-101 trial reports a median duration ...

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial First, patient-level correlation was confirmed using ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

Poster Presentation6543 Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia Sunday, June 19 a.m.-12 p.m. CDT Oral Presentation7501 ...

Routine Monitoring for MRD in Leukemia? It's Coming Detection of minimal residual disease (MRD) might predict outcome in Ph-positive ALL, which could help inform allogeneic stem cell transplant ...